Search Results
Search for other papers by Massimo Milione in
Google Scholar
PubMed
Search for other papers by Patrick Maisonneuve in
Google Scholar
PubMed
Search for other papers by Alessio Pellegrinelli in
Google Scholar
PubMed
Search for other papers by Federica Grillo in
Google Scholar
PubMed
Search for other papers by Luca Albarello in
Google Scholar
PubMed
Search for other papers by Paola Spaggiari in
Google Scholar
PubMed
Search for other papers by Alessandro Vanoli in
Google Scholar
PubMed
Search for other papers by Giovanna Tagliabue in
Google Scholar
PubMed
Search for other papers by Eleonora Pisa in
Google Scholar
PubMed
Search for other papers by Luca Messerini in
Google Scholar
PubMed
Clinical Research Lab (CRAB), Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Search for other papers by Giovanni Centonze in
Google Scholar
PubMed
Search for other papers by Frediano Inzani in
Google Scholar
PubMed
Search for other papers by Aldo Scarpa in
Google Scholar
PubMed
Search for other papers by Mauro Papotti in
Google Scholar
PubMed
Search for other papers by Marco Volante in
Google Scholar
PubMed
Search for other papers by Fausto Sessa in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
University of Milan, School of Medicine, Milan, Italy
Search for other papers by Giancarlo Pruneri in
Google Scholar
PubMed
Search for other papers by Guido Rindi in
Google Scholar
PubMed
Search for other papers by Enrico Solcia in
Google Scholar
PubMed
Search for other papers by Stefano La Rosa in
Google Scholar
PubMed
Search for other papers by Carlo Capella in
Google Scholar
PubMed
digestive system proposed the term ‘mixed adenoneuroendocrine carcinoma’ (MANEC) to define these cancers in which, by definition, each component represents at least 30% of the tumor mass ( Bosman et al . 2010 ). The pathogenesis of MANECs is still unclear
Search for other papers by Nora Sahnane in
Google Scholar
PubMed
Search for other papers by Daniela Furlan in
Google Scholar
PubMed
Search for other papers by Matilde Monti in
Google Scholar
PubMed
Search for other papers by Chiara Romualdi in
Google Scholar
PubMed
Search for other papers by Alessandro Vanoli in
Google Scholar
PubMed
Search for other papers by Emanuela Vicari in
Google Scholar
PubMed
Search for other papers by Enrico Solcia in
Google Scholar
PubMed
Search for other papers by Carlo Capella in
Google Scholar
PubMed
Search for other papers by Fausto Sessa in
Google Scholar
PubMed
Search for other papers by Stefano La Rosa in
Google Scholar
PubMed
, representing at least 30% of the neoplastic tissue, tumors are classified as mixed adenoneuroendocrine carcinomas (MANECs; Rindi et al . 2010 ). Both the exocrine and neuroendocrine components can have different morphological features, ranging from adenomas
Division of Cancer Sciences, University of Manchester, Manchester, UK
Search for other papers by Mairéad G McNamara in
Google Scholar
PubMed
Université Paris Sud, Faculté de Médecine de Bicêtre, Le Kremlin-Bicêtre, France
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Thomas Walter in
Google Scholar
PubMed
tumours in association with loss of MMR expression. These patients may be amenable to immune checkpoint inhibitor therapy. Sahnane et al. 2015 Not reported 89 (53 patients with NEC and 36 with MANEC) Microsatellite instability (MSI) in 12
Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Vivian Rosery in
Google Scholar
PubMed
Search for other papers by Henning Reis in
Google Scholar
PubMed
Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany
Search for other papers by Konstantinos Savvatakis in
Google Scholar
PubMed
Search for other papers by Bernd Kowall in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Martin Stuschke in
Google Scholar
PubMed
General, Visceral and Transplantation Surgery, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Search for other papers by Andreas Paul in
Google Scholar
PubMed
Department of Internal Medicine 6, Paracelsus Medical University, Nürnberg, Germany
Search for other papers by Alexander Dechêne in
Google Scholar
PubMed
Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany
Search for other papers by JiaJin Yang in
Google Scholar
PubMed
Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany
Search for other papers by Ben Zhao in
Google Scholar
PubMed
Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany
Search for other papers by Arianna Borgers in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Stefan Kasper in
Google Scholar
PubMed
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Martin Schuler in
Google Scholar
PubMed
Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany
Search for other papers by Phyllis F Cheung in
Google Scholar
PubMed
Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), Partner site University Hospital Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany
German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, Germany
Search for other papers by Jens T Siveke in
Google Scholar
PubMed
-neuroendocrine carcinoma (MANEC). In MiNEN, the Ki-67 index measurement and further analysis on the TME were solely performed in the neuroendocrine component. Data on clinical parameters were extracted from the pathologists’ original reports and the electronic health
Search for other papers by M Heetfeld in
Google Scholar
PubMed
Search for other papers by C N Chougnet in
Google Scholar
PubMed
Search for other papers by I H Olsen in
Google Scholar
PubMed
Search for other papers by A Rinke in
Google Scholar
PubMed
Search for other papers by I Borbath in
Google Scholar
PubMed
Search for other papers by G Crespo in
Google Scholar
PubMed
Search for other papers by J Barriuso in
Google Scholar
PubMed
Search for other papers by M Pavel in
Google Scholar
PubMed
Search for other papers by D O'Toole in
Google Scholar
PubMed
Search for other papers by T Walter in
Google Scholar
PubMed
Search for other papers by other Knowledge Network members in
Google Scholar
PubMed
/or chromogranin A (CgA) positivity, iii) GEP primary or of unknown primary and iv) Ki-67 index >20% or poorly differentiated morphology. Mixed tumors (MANEC) and NEN G3 without morphological differentiation available were excluded. Regarding quality of the
Search for other papers by O Hentic in
Google Scholar
PubMed
Search for other papers by P Hammel in
Google Scholar
PubMed
Search for other papers by A Couvelard in
Google Scholar
PubMed
Search for other papers by V Rebours in
Google Scholar
PubMed
Search for other papers by M Zappa in
Google Scholar
PubMed
Search for other papers by M Palazzo in
Google Scholar
PubMed
Search for other papers by F Maire in
Google Scholar
PubMed
Search for other papers by G Goujon in
Google Scholar
PubMed
Search for other papers by A Gillet in
Google Scholar
PubMed
Search for other papers by P Lévy in
Google Scholar
PubMed
Search for other papers by P Ruszniewski in
Google Scholar
PubMed
expression were at least required for each case) and classified according to the WHO 2010 classification ( Rindi et al . 2010 ). All patients with equivocal pathological diagnosis, that is, mixed tumors (MANEC according to the WHO 2010 classification
Search for other papers by M C F Mulders in
Google Scholar
PubMed
Search for other papers by Q G de Lussanet de la Sablonière in
Google Scholar
PubMed
Search for other papers by M L F van Velthuysen in
Google Scholar
PubMed
Search for other papers by E M Roes in
Google Scholar
PubMed
Search for other papers by J Hofland in
Google Scholar
PubMed
Search for other papers by W W de Herder in
Google Scholar
PubMed
selection. NOM, neuroendocrine ovarian metastases; MANEC, mixed adenoneuroendocrine carcinoma; NEC, neuroendocrine carcinoma; SSTR, somatostatin receptor; PRRT, peptide receptor radionuclide therapy; SSA, somatostatin analog. PFS First, we
Search for other papers by Tim J Takkenkamp in
Google Scholar
PubMed
Search for other papers by Mathilde Jalving in
Google Scholar
PubMed
Search for other papers by Frederik J H Hoogwater in
Google Scholar
PubMed
Search for other papers by Annemiek M E Walenkamp in
Google Scholar
PubMed
adenoneuroendocrine carcinomas (MANECs) included 53 NECs and 36 MANECs patients from several sites of origin. This study demonstrated that 12.4% of patients with either NECs or MANECs were MSI ( Sahnane et al. 2015 ). A study comparing well-differentiated NETs ( n
Search for other papers by Chiara Borga in
Google Scholar
PubMed
Search for other papers by Carlo Alberto Dal Pozzo in
Google Scholar
PubMed
Search for other papers by Elisabetta Trevellin in
Google Scholar
PubMed
Search for other papers by Francesca Bergamo in
Google Scholar
PubMed
Search for other papers by Sabina Murgioni in
Google Scholar
PubMed
Search for other papers by Anna Caterina Milanetto in
Google Scholar
PubMed
Search for other papers by Claudio Pasquali in
Google Scholar
PubMed
Search for other papers by Umberto Cillo in
Google Scholar
PubMed
Search for other papers by Giada Munari in
Google Scholar
PubMed
Search for other papers by Chiara Martini in
Google Scholar
PubMed
Search for other papers by Eugenio De Carlo in
Google Scholar
PubMed
Search for other papers by Vittorina Zagonel in
Google Scholar
PubMed
Search for other papers by Vincenza Guzzardo in
Google Scholar
PubMed
Search for other papers by Gianmaria Pennelli in
Google Scholar
PubMed
Search for other papers by Angelo Paolo Dei Tos in
Google Scholar
PubMed
Search for other papers by Roberto Vettor in
Google Scholar
PubMed
Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
Search for other papers by Matteo Fassan in
Google Scholar
PubMed
.e.exclusion of MANECs and other carcinomas with spots of neuroendocrine differentiation) and having adequate material for the immunohistochemical characterization and the matched loco-regional nodal locations (LNLs; diameter of the metastatic foci larger than 5
University College London Cancer Institute, Neuroendocrine Tumour Unit, 72 Huntley Street, London WC1E 6BT, UK
Search for other papers by A Karpathakis in
Google Scholar
PubMed
Search for other papers by H Dibra in
Google Scholar
PubMed
University College London Cancer Institute, Neuroendocrine Tumour Unit, 72 Huntley Street, London WC1E 6BT, UK
Search for other papers by C Thirlwell in
Google Scholar
PubMed
methylator phenotype; MANEC, mixed adenoneuroendocrine carcinoma. Chromatin remodellers in pNET In a recent study ( Jiao et al . 2011 ), exome sequencing was performed in ten sporadic pNETs followed by Sanger sequencing validation in a